Cargando…

Prognostic value of the standardized uptake value for (18)F-fluorodeoxyglucose in patients with stage IIIB melanoma

PURPOSE: FDG PET/CT is an excellent tool to detect melanoma metastases and also allows quantification of FDG uptake using standardized uptake value (SUV). The aim of this study was to prospectively investigate the potential prognostic value of SUV for disease-free survival (DFS) and disease-specific...

Descripción completa

Detalles Bibliográficos
Autores principales: Bastiaannet, E., Hoekstra, O. S., de Jong, J. R., Brouwers, A. H., Suurmeijer, A. J. H., Hoekstra, H. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3458194/
https://www.ncbi.nlm.nih.gov/pubmed/22801730
http://dx.doi.org/10.1007/s00259-012-2182-0
_version_ 1782244635433762816
author Bastiaannet, E.
Hoekstra, O. S.
de Jong, J. R.
Brouwers, A. H.
Suurmeijer, A. J. H.
Hoekstra, H. J.
author_facet Bastiaannet, E.
Hoekstra, O. S.
de Jong, J. R.
Brouwers, A. H.
Suurmeijer, A. J. H.
Hoekstra, H. J.
author_sort Bastiaannet, E.
collection PubMed
description PURPOSE: FDG PET/CT is an excellent tool to detect melanoma metastases and also allows quantification of FDG uptake using standardized uptake value (SUV). The aim of this study was to prospectively investigate the potential prognostic value of SUV for disease-free survival (DFS) and disease-specific survival (DSS) for patients with stage IIIB melanoma. METHODS: From November 2003 to March 2008, all consecutive patients were included in the present study. Inclusion criteria were: palpable, histology- or cytology-proven lymph node metastases of melanoma, and referred to the University Medical Centre Groningen for FDG PET and CT examination. Patients without distant metastases were evaluated. Multivariable survival analysis was performed to determine whether SUV was associated with DFS and DSS (Cox proportional hazard analysis). RESULTS: In 80 patients (without distant metastases, 65 %) SUV could be measured. Overall 5-year DFS was 41 % (95% CI 26–56 %) and 24 % (95% CI 12–38 %) in patients with a low and high SUVmean (p = 0.02), respectively. Overall 5-year DSS was 48 % (95% CI 31–62 %) and 30 % (95% CI 17–45 %) in patients with a low and high SUVmean (p = 0.04), respectively. In the multivariable analysis, SUVmean was associated with DFS (hazard ratio 1.7; p = 0.048), but was not associated with DSS (hazard ratio 1.6; p = 0.1). The number of positive nodes, extranodal growth and gender were also associated with survival. CONCLUSION: FDG uptake in clinically overt nodal melanoma metastases is inversely associated with DFS. Univariate analysis showed an association with DSS. However, after adjustment for potential confounders this association was no longer significant. If these findings are confirmed in larger studies, SUVmean could potentially be used (in addition to the number of positive nodes, tumour size and extranodal growth) as a factor in deciding on adjuvant systemic treatment. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00259-012-2182-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-3458194
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Springer-Verlag
record_format MEDLINE/PubMed
spelling pubmed-34581942013-07-15 Prognostic value of the standardized uptake value for (18)F-fluorodeoxyglucose in patients with stage IIIB melanoma Bastiaannet, E. Hoekstra, O. S. de Jong, J. R. Brouwers, A. H. Suurmeijer, A. J. H. Hoekstra, H. J. Eur J Nucl Med Mol Imaging Original Article PURPOSE: FDG PET/CT is an excellent tool to detect melanoma metastases and also allows quantification of FDG uptake using standardized uptake value (SUV). The aim of this study was to prospectively investigate the potential prognostic value of SUV for disease-free survival (DFS) and disease-specific survival (DSS) for patients with stage IIIB melanoma. METHODS: From November 2003 to March 2008, all consecutive patients were included in the present study. Inclusion criteria were: palpable, histology- or cytology-proven lymph node metastases of melanoma, and referred to the University Medical Centre Groningen for FDG PET and CT examination. Patients without distant metastases were evaluated. Multivariable survival analysis was performed to determine whether SUV was associated with DFS and DSS (Cox proportional hazard analysis). RESULTS: In 80 patients (without distant metastases, 65 %) SUV could be measured. Overall 5-year DFS was 41 % (95% CI 26–56 %) and 24 % (95% CI 12–38 %) in patients with a low and high SUVmean (p = 0.02), respectively. Overall 5-year DSS was 48 % (95% CI 31–62 %) and 30 % (95% CI 17–45 %) in patients with a low and high SUVmean (p = 0.04), respectively. In the multivariable analysis, SUVmean was associated with DFS (hazard ratio 1.7; p = 0.048), but was not associated with DSS (hazard ratio 1.6; p = 0.1). The number of positive nodes, extranodal growth and gender were also associated with survival. CONCLUSION: FDG uptake in clinically overt nodal melanoma metastases is inversely associated with DFS. Univariate analysis showed an association with DSS. However, after adjustment for potential confounders this association was no longer significant. If these findings are confirmed in larger studies, SUVmean could potentially be used (in addition to the number of positive nodes, tumour size and extranodal growth) as a factor in deciding on adjuvant systemic treatment. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00259-012-2182-0) contains supplementary material, which is available to authorized users. Springer-Verlag 2012-07-17 2012 /pmc/articles/PMC3458194/ /pubmed/22801730 http://dx.doi.org/10.1007/s00259-012-2182-0 Text en © The Author(s) 2012 https://creativecommons.org/licenses/by/4.0/ This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Article
Bastiaannet, E.
Hoekstra, O. S.
de Jong, J. R.
Brouwers, A. H.
Suurmeijer, A. J. H.
Hoekstra, H. J.
Prognostic value of the standardized uptake value for (18)F-fluorodeoxyglucose in patients with stage IIIB melanoma
title Prognostic value of the standardized uptake value for (18)F-fluorodeoxyglucose in patients with stage IIIB melanoma
title_full Prognostic value of the standardized uptake value for (18)F-fluorodeoxyglucose in patients with stage IIIB melanoma
title_fullStr Prognostic value of the standardized uptake value for (18)F-fluorodeoxyglucose in patients with stage IIIB melanoma
title_full_unstemmed Prognostic value of the standardized uptake value for (18)F-fluorodeoxyglucose in patients with stage IIIB melanoma
title_short Prognostic value of the standardized uptake value for (18)F-fluorodeoxyglucose in patients with stage IIIB melanoma
title_sort prognostic value of the standardized uptake value for (18)f-fluorodeoxyglucose in patients with stage iiib melanoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3458194/
https://www.ncbi.nlm.nih.gov/pubmed/22801730
http://dx.doi.org/10.1007/s00259-012-2182-0
work_keys_str_mv AT bastiaannete prognosticvalueofthestandardizeduptakevaluefor18ffluorodeoxyglucoseinpatientswithstageiiibmelanoma
AT hoekstraos prognosticvalueofthestandardizeduptakevaluefor18ffluorodeoxyglucoseinpatientswithstageiiibmelanoma
AT dejongjr prognosticvalueofthestandardizeduptakevaluefor18ffluorodeoxyglucoseinpatientswithstageiiibmelanoma
AT brouwersah prognosticvalueofthestandardizeduptakevaluefor18ffluorodeoxyglucoseinpatientswithstageiiibmelanoma
AT suurmeijerajh prognosticvalueofthestandardizeduptakevaluefor18ffluorodeoxyglucoseinpatientswithstageiiibmelanoma
AT hoekstrahj prognosticvalueofthestandardizeduptakevaluefor18ffluorodeoxyglucoseinpatientswithstageiiibmelanoma